Press release content from NewMediaWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from NewMediaWire
Press release content from NewMediaWire. The AP news staff was not involved in its creation.

Canadian Cannabis Success Being Replayed in Israel Right Now -- CFN Media

December 17, 2019 GMT

Seattle, WA - ( ) - December 17, 2019 - CFN Media (OTCQB: CNFN), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing   (CSE: IPOT) (OTC: ISCNF).After experiencing success with the legalization of cannabis in Canada, Darryl Jones was looking for the next big cannabis opportunity. As it happens, that opportunity was 11,000 miles away from Vancouver in Israel. Fast forward and Jones is now President and CEO of Isracann Biosciences, Israel’s first pure-play cannabis company to be listed in Canada and the U.S.“We started looking for other jurisdictions that were similar to Canada four or five years ago and Israel is a prime candidate,” Jones told CFN Media in a recent interview. Cannot view this video? Visit: While Israel indeed is following in the footsteps of Canada in many ways, it arguably has the richest history of cannabis research in the world, which provides a nice backstop when it comes to regulations, education and infrastructure. Add in nearly perfect climate for growing cannabis and new cannabis export laws and Isracann setting up headquarters in Israel is one savvy move.Jones, whose background is in the capital markets, is looking for his next success after taking cannabis/hemp pet product company True Leaf Medicine public in 2014 at a $10 million valuation and exiting just two years later at a $150 million valuation.First Crop in June 2020Isracann is fully funded to construct a 230,000 square-foot facility in Nil, a moshav in southern Israel. The company recently received   from the Israeli Land Authority and is soon expecting the final permits to initiate groundbreaking on the first phase of the project.Phase 1 will include building two 57,500 square-foot hybrid greenhouses and a packing facility with a 6,500 square-foot post-harvesting area, office space and kitchen for employees.Isracann, which has retained top firms in the Israeli cannabis industry to oversee the design and construction of the cutting edge facility, expects the build to be complete in six months. “We’re roughly timing June 2020 as first crop,” said Jones.Inexpensive (Really Inexpensive) Production CostsOnce the plants are harvested and dried, they will go on to Isracann’s in-country manufacturing partner to be turned into any number of products for the expanding domestic Israeli market. Israel has one of the highest per capita usage rates of medical cannabis in the world. Furthermore, the company intends to capitalize on the fact that Israel this year passed legislation permitting medical marijuana exports, making it only the third country to do so (Canada and Netherlands). Expectations are for the regulatory framework to be in place for exports from Israel to commence in mid-2020.That’s good timing for Isracann considering when it is expecting its first crops.Isracann is estimating the cost of production to be just C$0.40-C$0.60 per gram. To give that a little perspective, consider that production costs for cannabis producers in Canada are typically in the range of C$1-C$3 or higher per gram.That’s the type of huge opex difference that can give Isracann the ability to keep strong margins in the domestic market and a competitive advantage when it looks to the future and the massive European markets that are home to over 750 million people.Isracann already has a distribution partner for penetrating the European markets when that time comes. The first country on tap is Germany, the largest economy in the E.U. and a burgeoning medical cannabis market.“Made in Israel”When it comes to cannabis, Israel is a name recognized globally for its RD, venerable scientists and agriculture and high quality. To that point, it works as a branding badge for Isracann because distributors and retailers understand that cannabis from Israel is held to a high standard. In keeping with those standards, Isracann’s facilities will carry important accreditations, including Israeli Medical Cannabis Good Agricultural Practices (IMC-GAP), Israeli Medical Cannabis Good Security Practices (IMC-GSP) and European Union Good Manufacturing Practices (EU-GMP) certifications.Speaking to that, Jones said, ”[Israel] has 50+ years of cannabis research and they’re really starting to break open the doors on novel products and new formulations; We’re obviously very excited about that.“Stay tuned for Part 2 of Isracann’s CEO Darrryl Jones exclusive CFN Media executive video interview series.Click here to read the full article:  About CFN MediaCFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis industry.For Visitors and ViewersCFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.For Cannabis Businesses CompaniesCFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.Learn how to become a CFN Media client company, brand or entrepreneur: DisclaimerThe above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:  Investor RelationsToll Free: +1 855.205.0226Email:  Web:  Frank Lane206-369-7050